DDInter1642 DDInter171
Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.
Belantamab mafodotin, or GSK2857916, is an afucosylated monoclonal antibody that targets B cell maturation antigen conjugated to the microtubule disrupter monomethyl auristatin-F (MMAF). Belantamab mafodotin was granted FDA accelerated approval on 5 August 2020 for the treatment of multiple myeloma; however, its manufacturer began the process for withdrawal of the US marketing authorization in November 2022. In the meantime, belantamab mafodotin will be available for patients in the Risk Evaluation and Mitigation Strategy (REMS) program who can enrol in a compassionate use program.
Belantamab mafodotin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Filgrastim
Belantamab mafodotin {u} may lead to a major life threatening interaction when taken with {v} Tofacitinib
Belantamab mafodotin may cause a moderate interaction that could exacerbate diseases when taken with Filgrastim
Belantamab mafodotin may lead to a major life threatening interaction when taken with Tofacitinib